Dibenzoazepine defender: Drug found to be effective against resistant hepatitis C
December 29, 2017
Uncovering the Myths and Facts about Hepatitis C and Liver Cancer 
January 2, 2018
Show all

MS News Last Week: Mavenclad, Steroids, Blood Tests and Laquinimod

Here are some updates about multiple sclerosis therapies, testing, and diagnosis.

Canadians with relapsing-remitting multiple sclerosis (RRMS) can now receive Merck’s Mavenclad (cladribine tablets), now that Health Canada has approved Mavenclad as a therapy to reduce the frequency of MS exacerbations and delay disease progression.

Merck expects the drug to be commercially available by early January 2018 throughout Canada, which has the world’s highest MS rate.

Read full article: MS News Last Week: Mavenclad, Steroids, Blood Tests and Laquinimod

Read Full Article: MS News Last Week: Mavenclad, Steroids, Blood Tests and Laquinimod

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.